Drugs / Trivalent influenza vaccine (TIV)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00956046 | Sep 2009 → Jan 2011 | swine influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01232868 | Oct 2010 → Oct 2011 | influenza | Emory University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02550197 Comparator | Sep 2015 → Apr 2016 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trivalent Influenza vaccine (TIV) | “0.5 mL of a trivalent influenza vaccine (TIV) at Month 13” NCT00956046 ↗ |
| Known as | IIV3 | “the licensed split-virion trivalent inactivated influenza vaccine (IIV3) in the Republic of Korea” PMID 28933625 ↗ Nov 2017 |
| Modality | Vaccine | “trivalent influenza vaccine (TIV)” NCT00956046 ↗ |
| Route | Intramuscular | “0.5 ml IM as a single dose” NCT01232868 ↗ |